The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition

Medulloblastoma is comprised of at least four molecular subgroups with distinct clinical outcome (WHO classification 2016). SHH-TP53-mutated as well as MYC-amplified Non-WNT/Non-SHH medulloblastoma show the worst prognosis. Here we present evidence that single application of the multi-kinase inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Craveiro, Rogerio B, Ehrhardt, Michael, Velz, Julia, Olschewski, Martin, Goetz, Barbara, Pietsch, Torsten, Dilloo, Dagmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564532/
https://www.ncbi.nlm.nih.gov/pubmed/28159923
http://dx.doi.org/10.18632/oncotarget.14911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564532/
https://www.ncbi.nlm.nih.gov/pubmed/28159923
http://dx.doi.org/10.18632/oncotarget.14911

Ejemplares similares